Evidence map›Paper›PMID 42799151›Full record

ArticleRSC advances2026

BSA-based nanoassembly for combined chemo-photodynamic therapy of breast cancer.

Yunyang Zhao, Yingying Han, Yanni Zhang, Zaifeng Chen, Qiufang Gong, Jingbo Dong, Chao Liang

Abstract read
In one paragraph

Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yunyang ZhaoCixi Institute of Cancer Research, Cixi People's Hospital, Wenzhou Medical University Ningbo Zhejiang 315300 China liangchao@wmu.edu.cn.
Yingying HanInstitute for Advanced Research, Cixi Biomedical Research Institute, Wenzhou Medical University Wenzhou Zhejiang 325000 China.
Yanni ZhangCixi Institute of Cancer Research, Cixi People's Hospital, Wenzhou Medical University Ningbo Zhejiang 315300 China liangchao@wmu.edu.cn.
Zaifeng ChenCixi Institute of Cancer Research, Cixi People's Hospital, Wenzhou Medical University Ningbo Zhejiang 315300 China liangchao@wmu.edu.cn.
Qiufang GongCixi Institute of Cancer Research, Cixi People's Hospital, Wenzhou Medical University Ningbo Zhejiang 315300 China liangchao@wmu.edu.cn.
Jingbo DongCixi Institute of Cancer Research, Cixi People's Hospital, Wenzhou Medical University Ningbo Zhejiang 315300 China liangchao@wmu.edu.cn.
Chao LiangCixi Institute of Cancer Research, Cixi People's Hospital, Wenzhou Medical University Ningbo Zhejiang 315300 China liangchao@wmu.edu.cn.ORCID https://orcid.org/0000-0002-3885-7697

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The integration of photodynamic therapy and chemotherapy represents a promising strategy for precision cancer treatment, offering advantages including minimal invasiveness, reduced side effects, and enhanced therapeutic efficacy. In this study, we developed PTX/Ir@BSA nanoparticles through a self-assembly approach using bovine serum albumin (BSA) as a stabilizer to co-deliver the chemotherapeutic agent paclitaxel (PTX) and an iridium (Ir)-based photosensitizer. These nanoparticles demonstrated favorable stability and efficient reactive oxygen species (ROS) generation upon light irradiation.

Identifiers

PMID42799151
PMCPMC13614019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.